We are committed to using our advanced testing and analytics capabilities to support care management for COVID-19
Leveraging our existing testing capabilities, we’ve launched a diagnostic reverse transcription polymerase chain reaction (RT-qPCR) assay for COVID-19. PCR testing is one of the testing options authorized by the FDA to detect and track the spread of COVID-19.
It’s critical to act swiftly in the face of the COVID-19 pandemic and Tempus is committed to expanding lab capacity to test thousands of patients a day for COVID-19.
We offer customized programs based on different testing needs between organizations, agencies, and employers.
Building upon our next-generation sequencing infrastructure, Tempus is validating a comprehensive sequencing panel (Tempus|iD) which will cover a broad range of known respiratory ailments including COVID-19 and other common forms of coronavirus, pneumonia, influenza, rhinovirus, etc.
By differentiating whether a patient’s infection is caused by COVID-19 or a different strain of virus, and by providing consensus guidance for treatment and therapy, clinical decisions can be made with more complete information.
Additionally, the Tempus|iD panel returns a broader range of genomic sequencing for the virus, enabling further research and discovery.
Tempus|iD coming soon.
COVID-19 RESEARCH INITIATIVES
We are supporting the fight against COVID-19 by rapidly collecting and curating patient clinical data as well as performing full RNA transcriptome research sequencing for thousands of patients at no cost to institutions or patients.
We will collect clinical data for COVID-19 patients and apply our data abstraction expertise to structure a variety of record types and formats, helping researchers understand treatment and response patterns for patients battling the novel coronavirus.
Clinical data includes demographic information, symptoms, observations, and clinical notes, treatment and therapy history, and outcomes and results data.
By combining this clinical data with rich RNA sequencing data, Tempus will collaborate with research partners to advance research and discovery related to COVID-19.